However, the drug belonging to a treatment class known as SGLT2 inhibitors did not show a statistically significant benefit for the prevention of cardiac or stroke attacks even in patients diagnosed with cardiovascular disease.
Diabetic patients are at increased risk of heart problems, which allows cardiovascular drugs to benefit significantly from doctors and patients.
Stephen Wiviott from Brigham and the Boston Women's Hospital, a senior researcher in this nervous breakdown study, said that these findings are important in drawing a clear picture of SGLT2 medicines for carcass patients diagnosed so far.
AstraZeneca hopes that new data will help to extend Farxiga's use to a wider range of patients.
The main results of the Clinical Labor Declaration, which was conducted on a cohort of 17,000 patients, were first announced in September, but the details of the American Heart Association Annual Meeting were announced on Saturday and also published in the New England Journal of Medicine. . .
These results have shown that Farxiga reduces the risk of hospitalization due to heart problems and also the risk of kidney disease by 27%.
Two small studies of competing SGLT2 drugs focused on patients with diagnosed heart disease, Wiviott said, noting that the overall picture of the reported study showed widespread prevention of heart attacks was the main benefit.
"When we examine three studies, it is clear that this class is the primary benefit of cardiovascular medications is to reduce heart failure." Said.
For decades, diabetic patients have primarily focused on reducing blood glucose levels at certain levels. Wiviott shows, however, that a more holistic approach to diabetic susceptibility to other issues, such as heart failure, in which the five-year survival rate is only 50%.
Olabilir The current message can be as important as how we lower glucose levels. The doctor noted that patients should only select drugs that prolong the life of drugs that are effective in reducing blood glucose.
Farxiga competes with rival SGLT2 medicines, including Invarator Johnson & Johnson, who previously demonstrated the expected life expectancy for Jardiance by Eli Lilly and Boehringer Ingelheim, and the expected life expectancy for patients with a heart attack.
Since the AstraZeneca experiment evaluates patients who have not been diagnosed with cardiovascular disease, this study opens a wider market with primary prevention.
The Declare study did not identify increased amputation, fracture, bladder, or gangrene cancer risk in patients treated with Farxiga, sometimes seen in patients treated with SGLT, but increased genital infections.